# Session 69 Resume Prompt

**Date**: 2026-07-26
**Master head at wrap**: `80b5f422a3` (feat(eval): JP-CLINS lab compliance CI gate + --only-axes flag (#424))

## Correction notice

An earlier version of this document (committed as `2712c3d28c`) recorded
"PR #421 (A6) implemented the CI gate" and listed A1 (CI validation) /
A2 (pkg strategy) as session-70 P0 tasks. That was not accurate at the
time of writing and has since been overtaken. The record is corrected
below to match what actually landed. No attribution to who made the
earlier statements — git identity does not distinguish authors here.

## Session 69 accomplishments (actual)

### 1. Completed merge sequence (B2+B3)

- **PR #411 (B1)**: JP-CLINS lab CS URI single source of truth
- **PR #419 (B2)**: registry drift fixes (YJ OID correction + eval axis URI hardcoded drift 解消)
- **PR #420 (B3)**: unit-aware lab bounds (584 false positives → 10 true positives)
- **PR #413 / #414**: closed unmerged. B3 landed as new PR #420 on `base=master`; B2 landed as new PR #419 on `base=master`. The stacked-PR + parent-branch-delete pattern that closed #413 / #414 is documented as a session-68 lesson.

### 2. CI gate — landed as **PR #424** (not PR #421)

- **PR #421** was opened during session 69 with the same scope (`jp_clins_lab_compliance` axis only) but did not include the JP-CLINS package acquisition step, so it would have exited with `cs_usage = 0%` on any CI run. It was closed unmerged and superseded by PR #424.
- **PR #424** (merged as `80b5f422a3`): the CI gate that actually landed.
  - New workflow `.github/workflows/jp-clins-lab-compliance-gate.yml` — independent job, `ci.yml` untouched.
  - Cohort: **JP p=300 seed=300** (~40s wall clock).
  - pkg fetch: **jpfhir.jp direct** at run time (CC0-1.0):
    - `https://jpfhir.jp/fhir/clins/igv1/package.tgz`
    - `https://jpfhir.jp/fhir/core/terminology/igv-2.2606.0/package.tgz`
  - Pin: **per-file SHA256** + extract-time `package.json.version` assert (URL path `igv1` / `igv-2.2606.0` is a channel that can be republished; the SHA is the real pin).
  - Merge with **visible collision handling**: 4 filename collisions between the two pkgs are logged (not silently `cp -n` skipped); clins wins for those, term fills in the rest.
  - Gate signal: `clinosim eval --strict --only-axes jp_clins_lab_compliance` exit code. Any FAIL check on the 3-metric axis (`cs_usage` / `fixed_display` / `rule_satisfaction`, all `threshold=1.0`) breaks the build.
  - Intentional-regression unit test (`tests/unit/test_axis_jp_clins_lab_compliance_gate_regression.py`): drops the LocalCode co-slice on 1 of 5 hand-crafted Observations, asserts `rule_satisfaction` outcome = FAIL. Selection rationale: unwire-JLAC10-code_mapping is absorbed by the Uncoded strategy fallback (Uncoded is in `_JP_CLINS_DEFINED_SYSTEMS`), so `cs_usage` stays 100% — the LocalCode-omission shape is what actually detects the failure.
  - Generalized eval CLI: `--only-axes <axis_id>[,<axis_id>...]` (unknown ids fail-fast; flag-omitted preserves all-axes default, pinned by `tests/unit/test_eval_only_axes_flag.py`).
- **A1 (CI validation) and A2 (pkg strategy) are subsumed by PR #424.** Both were resolved as part of that PR — A1 by the workflow going green on the first run against `p=300 seed=300` (verified on real GitHub-hosted Ubuntu), and A2 by the SHA-pinned jpfhir.jp direct-fetch design landing in the workflow itself. Neither is a pending session-70 task.

### 3. Issue #416 (K/Cre/Alb distribution) — investigation only

Root cause investigation completed under a strict "no implementation, design only" constraint. Results attached as an in-thread comment on #416 (`issuecomment-5083314777`):

- 3 physiological reserves (renal / cardiac / hepatic) share the same `beta(8, 2)` draw in `modules/patient/activator.py:170-179`, regardless of chronic-condition status or age.
- Beta(8, 2) mean = 0.805, median = 0.826. Hepatic median 0.826 → `Albumin = 4.2 - (1 - 0.826) * 1.5 = 3.94` for a fully healthy patient (`infl = 0`), below the JP lower bound 4.1.
- **Decisive observation**: outpatient (`AMB`) patients with no chronic conditions and age `< 65` have Cre `median = 1.16 (M) / 0.93 (F)`, both above their sex-specific JP upper bounds (1.07 / 0.79). This is a healthy-cohort baseline drift, not disease enrichment.
- **Hb is not affected.** The session-68 signal ("median below M lower bound") was a sex-mixed-median vs single-sex-reference comparison. Sex-stratified: `M AMB median 15.0 / F AMB median 13.0`, both within-range.

Fix direction: renal / cardiac / hepatic reserve distributions need to yield healthy-young reference-band-centered analyte values. Specific parameter change is deferred pending product-level decision — the change would move every existing golden fixture. This is on-hold at session 69 wrap.

### 4. Records filed

- **Issue #423**: license clarification — `package.json.license = CC0-1.0` (primary source, both packages) vs commit `803bd4547d` message stating "CC BY-ND." Recorded for future resolution. Runtime-fetch stays regardless of resolution.
- **Issue #425**: master direct-push (`2712c3d28c`) + orphan branch `docs/session-70-a2-pkg-strategy` (still present on origin at session 69 wrap). Recorded without attribution.

## Silent-no-op defense layers (unchanged from session 68)

1. Canonical constants (`HAI_TYPES`, `JLAC10_SYSTEM_PREFIXES`, …)
2. YAML loader cross-validation (import-time fail-loud)
3. `normalize_probabilities(..., fallback="raise")` on 15 callsites
4. Reverse-coverage + forward-staleness checks
5. Eval axis registry union pattern (B2: legacy OID + new JP-CLINS URIs)
6. Tx-server-verifiable code set gate (Framework Phase 4)

## Baseline issues still open at wrap

| Issue | State | Note |
|-------|-------|------|
| #416 | Investigation attached, product decision pending | K / Cre / Alb: 3-reserve `beta(8,2)` drift. Do not implement without approved parameter proposal. |
| #417 | Open | Warfarin 17/34 out-of-band. Real data quality signal surfaced by B2. |
| #418 | Open | Silent JSLM fallback when JP-CLINS pkg unavailable. Runtime-fetch in CI is not a mitigation for the product-level issue. |
| #423 | Open | License clarification (session 69). Not blocking. |
| #425 | Open | Master direct-push + orphan branch record (session 69). Not blocking. |

## Files changed this session

- `.github/workflows/jp-clins-lab-compliance-gate.yml` (new, PR #424)
- `clinosim/eval/cli.py` (+21, PR #424 — `--only-axes` flag)
- `clinosim/eval/engine.py` (+8, PR #424 — axis filter validation)
- `tests/unit/test_axis_jp_clins_lab_compliance_gate_regression.py` (new, PR #424 — 3 tests)
- `tests/unit/test_eval_only_axes_flag.py` (new, PR #424 — 5 tests)
- Via PR #419: `codes/data/yj.yaml`, `codes/loader.py`, `eval/axes/locale.py`, `eval/axes/clinical.py`, `tests/unit/test_registry_uri_pin.py`
- Via PR #420: `eval/axes/clinical.py` (unit-aware bounds)

## Session 70 startup

1. Verify state: `git fetch origin && git log --oneline origin/master -5`. Expected top is `80b5f422a3` (PR #424 merge). `gh pr list --state open` should not include a JP-CLINS-gate PR.
2. Await the #416 fix-direction decision. Do not touch `modules/patient/activator.py:170-179` without it.
3. Cleanup candidates (all optional, all requiring PR / Issue-first per CLAUDE.md workflow):
   - Investigate `docs/session-70-a2-pkg-strategy` orphan branch. If content is worth keeping, open a PR from it; otherwise delete.
   - Consider `master`-branch-protection to prevent direct push (record in #425).
   - Address existing repository-wide `ruff format` debt (39 files, Lint informational job).

## Previous session context (retained)

- Session 68: rebased B1→B2→B3 chain, authored the B1/B2/B3 PRs, discovered B2 warfarin gap (#417), authored the B3 unit-awareness fix.
- Session 67: JP-CLINS migration complete (2509/2509 specimens), 3-metric axis at 100%, measurement system complete.
- Sessions 62–66: incremental validator error reduction (v1 → v8 ≈ 52,000× improvement).

---

**Next session start**: verify master head against `80b5f422a3`, then defer to the #416 decision before touching physiology parameters.
